HER2- Mutation Testing Considerations and Timing

Key Takeaways

• Integrating HER2-directed therapies into NSCLC decision-making requires adapting protocols and ensuring timely updates as new therapies emerge.
• Streamlined processes and enhanced communication among multidisciplinary teams are crucial for incorporating new data and therapies.
• HER2-mutation testing turnaround time varies, and interpreting results can be complex, requiring clear guidelines and expert input.
• Efficient integration necessitates collaboration, continuous education, and robust systems to manage evolving therapeutic landscapes.